loader2
Login Open ICICI 3-in-1 Account
IPOLogoImag

MANKIND PHARMA LTD IPO

IPO Details

ICICI Direct Research Rating : SUBSCRIBE
-
-
13 shares
-
₹ 1026 – 1080
₹ Up to 4,326 crores

Issue timeline

  • -
  • 03-May-2023
  • 04-May-2023
  • 05-May-2023
  • 08-May-2023

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

- India’s fourth largest pharmaceutical company in terms of Domestic Sales and second largest in terms of sales volume for the Financial Year 2022 (Source:  Company DRHP)
- The company has 36 brands in pharmaceutical business that have each achieved over ₹500.00 million in Domestic Sales in the Financial Year 2022(Source: Company DRHP)

Strengths & Risks

Strengths (3)

Scaled domestic focused business with potential for further growth
The company is among the largest domestic formulations businesses in India with Domestic Sales of approximately ₹82,198 million during the Financial Year 2022, ranking fourth in the IPM in terms of Domestic Sales (Source:IQVIA Dataset, IQVIA TSA MAT March 2022 Dataset for India (For FY20-22)) and Company DRHP)

Risks (2)

Subject to extensive government regulations which are also subject to change
The company operate in a highly regulated industry and their operations, including development, testing, research, manufacturing, marketing and sales activities, are subject to extensive laws and regulations in India and other countries.Changes in the laws and regulations may lead to uncertainty in operations and increase compliance costs, which may adversely affect business(Source: Company DRHP)

Financials

Industry Overview

- Growth in lifestyle diseases: Chronic segment in IPM has grown at a relatively faster rate of 12.29% CAGR compared to the overall IPM (10.93%) over Financial Year 2018-22. Market share of chronic segment increased from 34.71% in Financial Year 2018 to 38.26% in Financial Year 2021 (Source: IQVIA TSA MAT Mar'20, IQVIA TSA MAT Mar'22).
- Overall market size and estimated growth rate : The global formulation market was estimated at US$ 1,288.83 billion (₹ 96,662.25 billion) in Financial Year 2022 (Source: IQVIA MIDAS Quarterly Sales Data MAT March 2022) and is expected to grow at a CAGR of 4.5-5% to reach US$ 1,600-1,650 billion (₹ 120,000-123,750 billion) by Financial Year 2027 (Source: IQVIA Market Prognosis – May 2022 Source: Company DRHP)

Mankind Pharma IPO FAQs

What is the lot size of Mankind Pharma IPO?

The lot size is 13 shares for Mankind Pharma IPO

Mankind Pharma IPO is mainboard IPO of 40,058,844 equity shares with face value of ₹1 aggregating upto Rs.4,326.36 Crores

Mankind Pharma IPO opens from April 25th,2023 and closes on April 27th,2023 for subscription.

Mankind Pharma IPO shares will be allotted on May 3rd ,2023

Mankind Pharma IPO listing date is May 8th,2023

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.